SEC I	Form 4
-------	--------

Instruction 1(b)

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

						,				,								
1. Name and Address of Reporting Person [*] Baroldi Joseph					2. Issuer Name and Ticker or Trading Symbol <u>IONIS PHARMACEUTICALS INC</u> [IONS]							S (Che	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner V Officer (give title Other (specify					
(Last) (First) (Middle) 2855 GAZELLE COURT					3. Date of Earliest Transaction (Month/Day/Year) 10/01/2023								X Oncer (give tute Other (specify below) below) EVP, Chief Business Officer					
(Street) CARLSBAD CA 92010				4.1	4. If Amendment, Date of Original Filed (Month/Day/Year)							Line	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City) (State) (Zip)				R	Rule 10b5-1(c) Transaction Indication													
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.									to									
		Tab	le I - Non-De	rivativ	e Se	curitie	s A	cquired, D	ispos	ed o	f, or Ber	neficial	y Owned					
1. Title of Security (Instr. 3) 2. Transau Date (Month/Date)					Execution Date,			Code (Ins	Transaction Disposed Of (D) (Instr. 3, 4 Code (Instr. 5)			d (A) or r. 3, 4 and	Beneficia	es Fo ally (D following (I)	Form (D) o	rm: Direct or Indirect (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code V				Am	nount	t (A) or (D) Pi		Transact (Instr. 3 a	tion(s)					
		-	Fable II - Deri (e.g.					quired, Dis s, options					Owned					
1. Title of Derivative Security (Instr. 3)	ve Conversion Date Execution Date, or Exercise (Month/Day/Year) if any		Code (ransaction of Code (Instr. Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)		Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)				
				Code	v	(A)	(D)	Date Exercisable	Expira Date	ation	Title	Amount or Number of Shares						
Non- Qualified Stock Option (right to buy)	\$45.36	10/01/2023		A		2,400		10/01/2024 ⁽¹⁾	09/30/	/2034	Common Stock	2,400	\$0.0	2,400)	I	by Spouse	

Explanation of Responses:

1. Grant on 10/1/2023 to reporting person's spouse of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 10/1/2023. 25% of the shares subject to the option will vest and become exercisable on 10/1/2024. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years.



** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.